References

1. Manji, R.A.; Lee, W.; Cooper, D.K.C. Xenograft bioprosthetic heart valves: Past, present and future. Int. J. Surg. 2015, 23 Pt. B, 280–284.
2. Soares, J.S.; Feaver, K.R.; Zhang, W.; Kamensky. D.; Aggarwal, A.; Sacks, M.S. Biomechanical behavior of bioprosthetic heart valve heterograft tissues: Characterization, simulation, and performance. Cardiovasc. Eng. Technol. 2016, 7, 309–351.
3. Goldstone, A.B.; Chiu, P.; Baiocchi, M.; Lingala. B.; Patrick, W.L.; Fischbein, M.P.; Woo, Y.J. Mechanical or biologic prosthe-ses for aortic-valve and mitral-valve replacement. N. Engl. J. Med. 2017, 377, 1847–1857.
4. Wang, M.; Furnary, A.P.; Li, H.F.; Grunkemeier, G.L. Bioprosthetic aortic valve durability: A meta-regression of published studies. Ann. Thorac. Surg. 2017, 104, 1080–1087.
5. Head, S.J.; Çelik, M.; Kappetein, A.P. Mechanical versus bioprosthetic aortic valve replacement. Eur. Heart J. 2017, 38, 2183–2191.
6. Stein, P.D.; Wang, C.H.; Riddle, J.M.; Magilligan, D.J., Jr. Leukocytes, platelets, and surface microstructure of spontaneously degenerated porcine bioprosthetic valves. J. Card. Surg. 1988, 3, 253–261.
7. Grabenwöger, M.; Fitzal, F.; Gross, C.; Hutschala, D.; Böck, P.; Brucke, P.; Wolner, E. Different modes of degeneration in autologous and heterologous heart valve prostheses. J. Heart Valve Dis. 2000, 9, 104–111.
8. Manji, R.A.; Zhu, L.F.; Nijjar, N.K.; Rayner, D.C.; Korbutt, G.S.; Churchill, T.A.; Rajotte, R.V.; Koshal, A.; Ross, D.B. Glutar-aldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection. Circulation 2006, 114, 318–327.
9. Wilhelmi, M.H.; Mertsching, H.; Wilhelmi, M.; Leyh, R.; Haverich, A. Role of inflammation in allogeneic and xenogeneic heart valve degeneration: Immunohistochemical evaluation of inflammatory endothelial cell activation. J. Heart Valve Dis. 2003, 12, 520–526.
10. Siddiqui, R.F.; Abraham, J.R.; Butany, J. Bioprosthetic heart valves: Modes of failure. Histopathology 2009, 55, 135–144.
11. Nair, V.; Law, K.B.; Li, A.Y.; Phillips, K.R.; David, T.E.; Butany, J. Characterizing the inflammatory reaction in explanted Medtronic Freestyle stentless porcine aortic bioprosthesis over a 6-year period. Cardiovasc. Pathol. 2012, 21, 158–168.
12. Vesely, I. Heart valve tissue engineering. Circ. Res. 2005, 97, 743–755.
13. Bloch, O.; Golde, P.; Dohmen, P.M.; Posner, S.; Konertz, W.; Erdbrügger, W. Immune response in patients receiving a bio-prosthetic heart valve: Lack of response with decellularized valves. Tissue Eng. Part. A 2011, 17, 2399–2405.
14. Ramm, R.; Hilfiker, A. After decellularization of porcine heart valves: Non Gal antigenic epitopes detectable by non-conditioned human sera. Xenotransplantation 2014, 21, 193.
15. Nam, J.; Choi, S.Y.; Sung, S.C.; Lim, H.G.; Park, S.S.; Kim, S.H.; Kim, Y.J. Changes of the structural and biomechanical prop-erties of the bovine pericardium after the removal of α-gal epitopes by decellularization and α-galactosidase treatment. Korean J. Thorac. Cardiovasc. Surg. 2012, 45, 380–389.
16. Erdbrügger, W.; Konertz, W.; Dohmen, P.M.; Posner, S.; Ellerbrok, H.; Brodde, O.E.; Robenek, H.; Modersohn, D.; Pruss, A.; Holinski, S.; et al. Decellularized xenogenic heart valves reveal remodeling and growth potential in vivo. Tissue Eng. 2006, 12, 2059–2068.
17. Bastian, F.; Stelzmuller, M.E.; Kratochwill, K.; Kasimir, M.T.; Simon, P.; Weigel, G. IgG deposition and activation of the classical complement pathway involvement in the activation of human granulocytes by decellularized porcine heart valve tissue. Biomaterials 2008, 29, 1824–1832.
18. Helder, M.R.K.; Stoyles, N.J.; Tefft, B.J.; Hennessy, R.S.; Hennessy, R.R.C.; Dyer, R.; Witt, T.; Simari, R.D.; Lerman, A. Xeno-antigenicity of porcine decellularized valves. J. Cardiothorac. Surg. 2017, 12, 56.
19. Ruffer, A.; Purbojo, A.; Cicha, I.; Glöckler, M.; Potapov, S.; Dittrich, S.; Cesnjevar, R.A. Early failure of xenogenous de-cellularised pulmonary valve conduits—A word of caution! Eur. J. Cardiothorac. Surg. 2010, 38, 78–85.
20. Liao, J.; Joyce, E.M.; Sacks, M.S. Effects of decellularization on the mechanical and structural properties of the porcine aortic valve leaflet. Biomaterials 2008, 29, 1065–1074.
21. Choi, S.Y.; Jeong, H.J.; Lim, H.G.; Park, S.S.; Kim, S.H.; Kim, Y.J. Elimination of α-gal xenoreactive epitope: -galactosidase treatment of porcine heart valves. J. Heart Valve Dis. 2012, 21, 387–397.
22. Lim, H.-G.; Choi, S.Y.; Yoon, E.J.; Kim, S.H.; Kim, Y.J. In vivo efficacy of α-galactosidase as possible promise for prolonged durability of bioprosthetic heart valve using 1,3-galactosyltransferase knockout mouse. Tissue Eng. A 2013, 19, 2339–2348.
23. Liu, Q.P.; Sulzenbacher, G.; Yuan, H.; Bennett, E.P.; Pietz, G.; Saunders, K.; Spence, J.; Nudelman, E.; Levery, S.B.; White, T. et al. Bacterial glycosidases for the production of universal red blood cells. Nat. Biotechnol. 2007, 25, 454–464.
24. Smood, B.; Hara, H.; Cleveland, D.C.; Cooper, D.K.C. In Search of the ideal valve: Optimizing genetic modifications to pre-vent bioprosthetic degeneration. Ann. Thorac. Surg. 2019; 108, 624–635.
25. Zhang, R.; Wang, Y.; Chen, L.; Wang, R.; Li, C.; Li, X.; Fang, B.; Ren, X.; Ruan, M.; Liu, J. et al. Reducing immunoreactivity of porcine bioprosthetic heart valves by genetically-deleting three major glycan antigens, GGTA1/β4GalNT2/CMAH. Acta Bio-mater. 2018; 72, 196–205.
26. Lutz, A.J.; Li, P.; Estrada, J.L.; Sidner, R.A.; Chihara, R.K.; Downey, S.M.; Burlak, C.; Wang, Z.Y.; Reyes, L.M.; Ivary, B. et al. Double knockout pigs deficient in N-glycolylneuraminic acid and galactose α-1,3-galactose reduce the humoral barrier to xenotransplantation. Xenotransplantation 2013; 20, 27–35.
27. Wagner F.; Holzapfel B.M.; McGovern J.A.; Shafiee A.; Baldwin J.G.; Martine L.C.; Lahr C.A.; Wunner F.M.; Friis T.; Bas O.; et al. Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma. Biomaterials. 2018, 171, 230–246.
28. Galili, U.; Rachmilewitz, E.A.; Peleg, A.; Flechner, I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J. Exp. Med. 1984, 160, 1519–1531.
29. Towbin, H.; Rosenfelder, G.; Wieslander, J.; Avila, J.L.; Rojas, M.; Szarfman, A.; Esser, K.; Nowack, H.; Timpl, R. Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis, and normal individuals recognize ter-minal galactosyl [α1-3]-galactose epitopes. J. Exp. Med. 1987, 166, 419–432.
30. Parker, W.; Lin, S.S.; Yu, P.B.; Sood, A.; Nakamura, Y.C.; Song, A.; Everett, M.L.; Platt, J.L. Naturally occurring an-ti-α-galactosyl antibodies: Relationship to xenoreactive anti-α-galactosyl antibodies. Glycobiology 1999, 9, 865–873.
31. McMorrow, I.M.; Comrack, C.A.; Sachs, D.H.; DerSimonian, H. Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal [α1,3] Galactose epitope. Transplantation 1997, 64, 501–510.
32. Galili, U.; Macher, B.A.; Buehler, J.; Shohet, S.B. Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1 → 3)-linked galactose residues. J. Exp. Med. 1985, 162, 573–582.
33. Galili, U.; Clark, M.R.; Shohet, S.B.; Buehler, J.; Macher, B.A. Evolutionary relationship between the anti-Gal antibody and the Galα13Gal epitope in primates. Proc. Natl. Acad. Sci. USA 1987, 84, 1369–1373.
34. Teneberg, S.; Lönnroth, I.; Torres Lopez, J.F.; Galili, U.; Halvarsson, M.O.; Angström, J.; Karlsson, K.A. Molecular mimicry in the recognition of glycosphingolipids by Galα3Galß4GlcNAcß-binding Clostridium difficile toxin A, human natural an-ti-α-galactosyl IgG and the monoclonal antibody Gal-13: Characterization of a binding-active human glycosphingolipid, non-identical with the animal receptor. Glycobiology 1996, 6, 599–609.
35. Galili, U.; Shohet, S.B.; Kobrin, E.; Stults, C.L.M.; Macher, B.A. Man, apes, and Old World monkeys differ from other mam-mals in the expression of α-galactosyl epitopes on nucleated cells. J. Biol. Chem. 1988, 263, 17755–17762.
36. Oriol, R.; Candelier, J.J.; Taniguchi, S.; Balanzino, L.; Peters, L.; Niekrasz, M.; Hammer, C.; Cooper, D.K. Major carbohydrate epitopes in tissues of domestic and African wild animals of potential interest for xenotransplantation research. Xenotrans-plantation 1999, 6, 79–89.
37. Teranishi, K.; Mañez, R.; Awwad, M.; Cooper, D.K. Anti-Gal α1-3Gal IgM and IgG antibody levels in sera of humans and Old World non-human primates. Xenotransplantation 2002, 9, 148–154.
38. Good, A.H.; Cooper, D.C.K.; Malcolm, A.J.; Ippolito, R.M.; Koren, E.; Neethling, F.A.; Ye, Y.; Zuhdi, N.; Lamontagne, L.R. Identification of carbohydrate structures which bind human anti-porcine antibodies: Implication for discordant xenograft-ing in man. Transplant. Proc. 1992, 24, 559–562.
39. Galili, U. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: A major obstacle for xenotransplantation in humans. Immunol. Today 1993, 14, 480–482.
40. Sandrin, M.S.; Vaughan, H.A.; Dabkowski, P.L.; McKenzie, I.F.C. Anti-pig IgM antibodies in human serum react predomi-nantly with Gal (αl-3)Gal epitopes. Proc. Natl. Acad. Sci. USA 1993, 90, 11391–11395.
41. Cooper, D.K.C.; Good, A.H.; Koren, E.; Oriol, R.; Malcolm, A.J.; Ippolito, R.M.; Neethling, FA.; Ye. Y.; Romano, E.; Zuhdi, N. Identification of α-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: Relevance to discordant xenografting in man. Transpl. Immunol. 1993, 1, 198–205.
42. Collins, B.H.; Cotterell, A.H.; McCurry, K.R.; Alvarado, C.G.; Magee, J.C.; Parker, W.; Platt, J.L. Cardiac xenografts between primate species provide evidence for the importance of the a-galactosyl. determinant in hyperacute rejection. J. Immunol. 1995, 154, 5500–5510.
43. Xu, Y.; Lorf, T.; Sablinski, T.; Gianello, P.; Bailin, M.; Monroy, R.; Kozlowski, T.; Awwad, M.; Cooper, D.K.; Sachs, D.H. Re-moval of anti-porcine natural antibodies from human and nonhuman primate plasma in vitro and in-vivo by a Galα1-3Galβ1-4βGlc-X immunoaffinity column. Transplantation 1998, 65, 172–179.
44. Simon, P.M.; Neethling, F.A.; Taniguchi, S.; Goode, P.L.; Zopf, D.; Hancock, W.W.; Cooper, D.K. Intravenous infusion of Galα-1-3Gal oligosaccharides in baboons delays hyperacute rejection of porcine heart xenografts. Transplantation 1998, 65, 346–353.
45. Galili, U.; Anaraki, F.; Thall, A.; Hill-Black, C.; Radic, M. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 1993, 82, 2485–2493.
46. Galili, U.; Mandrell, R.E.; Hamadeh, R.M.; Shohet, S.B.; Griffiss, J.M. Interaction between human natural anti-α-galactosyl immunoglobulin G and bacteria of the human flora. Infect. Immun. 1988, 56, 1730–1737.
47. Posekany, K.J.; Pittman, H.K.; Bradfield, J.F.; Haisch, C.E.; Verbanac, K.M. Induction of cytolytic anti-Gal antibodies in α-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86, B7 bacteria. Infect. Immun. 2002, 70, 6215–6222.
48. Mañez, R.; Blanco, F.J.; Díaz, I.; Centeno, A.; Lopez-Pelaez, E.; Hermida, M.; Davies, H.F.; Katopodis, A. Removal of bowel aerobic gram-negative bacteria is more effective than immunosuppression with cyclophosphamide and steroids to decrease natural α-galactosyl IgG antibodies. Xenotransplantation 2001, 8, 15–23.
49. Konakci, K.Z.; Bohle, B.; Blumer, R.; Hoetzenecker, W.; Roth, G.; Moser, B.; Boltz-Nitulescu, G.; Gorlitzer, M.; Klepetko, W.; Wolner, E. et al. α-Gal on bioprostheses: Xenograft immune response in cardiac surgery. Eur. J. Clin. Investig. 2005, 35, 17–23.
50. Mangold, A.; Szerafin, T.; Hoetzenecker, K.; Hacker, S.; Lichtenauer, M.; Niederpold, T.; Nickl, S.; Dworschak, M.; Blumer, R.; Auer, J. et al. α-Gal specific IgG immune response after implantation of bioprostheses. Thorac. Cardiovasc. Surg. 2009, 57, 191–195.
51. Park, C.S.; Oh, S.S.; Kim, Y.E.; Choi, S.Y.; Lim, H.G.; Ahn, H.; Kim, Y.J. Anti-α-Gal antibody response following xenogeneic heart valve implantation in adults. J. Heart Valve Dis. 2013, 22, 222–229.
52. Park, C.S.; Park, S.S.; Choi, S.Y.; Yoon, S.H.; Kim, W.H.; Kim, Y.J. Anti α-gal immune response following porcine biopros-thesis implantation in children. J. Heart Valve Dis. 2010, 19, 124–130.
53. Stone, K.R.; Walgenbach, A.W.; Turek, T.J.; Somers, D.L.; Wicomb, W.; Galili, U. Anterior cruciate ligament reconstruction with a porcine xenograft: A serologic, histologic, and biomechanical study in primates. Arthroscopy 2007, 23, 411–419.
54. Stone, K.R.; Ayala, G.; Goldstein, J.; Hurst, R.; Walgenbach, A.; Galili, U. Porcine cartilage transplants in the cynomolgus monkey. III. Transplantation of α-galactosidase-treated porcine cartilage. Transplantation 1998, 65, 1577–1583.
55. Lila, N.; McGregor, C.G.; Carpentier, S.; Rancic, J.; Byrne, G.W.; Carpentier, A. Gal knockout pig pericardium: New source of material for heart valve bioprostheses. J. Heart Lung Transplant. 2010, 29, 538–543.
56. McGregor, C.G.; Carpentier, A.; Lila, N.; Logan, J.S.; Byrne, G.W. Cardiac xenotransplantation technology provides materi-als for improved bioprosthetic heart valves. J. Thorac. Cardiovasc. Surg. 2011, 141, 269–275.
57. Galili, U.; Tibell, A.; Samuelsson, B.; Rydberg, L.; Groth, C.G. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. Transplantation 1995, 59, 1549–1556.
58. Galili, U.; Chen, Z.C.; Tanemura, M.; Seregina, T.; Link, C.J. Understanding the induced antibody response (in xenograft recipients). GRAFT 2001, 4, 32–35.
59. Galili, U. The Natural Anti-Gal Antibody as Foe Turned Friend in Medicine; Elsevier/Academic Press: London, UK, 2018; p. 14.
60. Lai, L.; Kolber-Simonds, D.; Park, K.W.; Cheong, H.T.; Greenstein, J.L.; Im, G.S.; Samuel, M.; Bonk, A.; Rieke, A.; Day, B.N. et al. Production of α-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002, 295, 1089–1092.
61. Phelps, C.J.; Koike, C.; Vaught, T.D.; Boone, J.; Wells, K.D.; Chen, S.H.; Ball, S.; Specht, S.M.; Polejaeva, I.A.; Monahan, J.A. et al. Production of α1,3-galactosyltransferase-deficient pigs. Science 2003, 299, 411–414.
62. Merrick, J.M.; Zadarlik, K.; Milgrom, F. Characterization of the Hanganutziu-Deicher [serum-sickness] antigen as gangliosides containing N-glycolylneuraminic acid. Int. Arch. Allergy Appl. Immunol. 1978, 57, 477–480.
63. Zhu, A.; Hurst, R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002, 9, 376–381.
64. Nguyen, D.H.; Tangvoranuntakul, P.; Varki, A. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J. Immunol. 2005, 175, 228–236.
65. Muchmore, E.A.; Diaz, S.; Varki, A. A structural difference between the cell surfaces of humans and the great apes. Am. J. Phys. Anthropol. 1998, 107, 187–198.
66. Gagneux, P.; Varki, A. Evolutionary considerations in relating oligosaccharide diversity to biological function. Glycobiology 1999, 9, 747–755.
67. Varki, A. Colloquium paper: Uniquely human evolution of sialic acid genetics and biology. Proc. Natl. Acad. Sci. USA 2010, 107 (Suppl. S2), 8939–8946.
68. Padler-Karavani, V.; Yu, H.; Cao, H.; Chokhawala, H.; Karp, F.; Varki, N.; Chen, X.; Varki, A. Diversity in specificity, abun-dance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease. Glycobiology 2008, 18, 818–830.
69. Padler-Karavani ,V.; Varki, A. Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk. Xenotransplantation 2011, 18, 1–5.
70. Galili, U. Induced anti-non gal antibodies in human xenograft recipients. Transplantation 2012, 93, 11–16.
71. Stone, K.R.; Abdel-Motal, U.; Walgenbach, A.W.; Turek, T.J.; Galili, U. Replacement of human anterior cruciate ligaments with pig ligaments: A model for anti-non-gal antibody response in long-term xenotransplantation. Transplantation 2007, 83, 211–219.
72. Singer, A.J.; Clark, R.A. Cutaneous wound healing. N. Engl. J. Med. 1999, 341, 738–746.
73. Koh, T.J.; DiPietro, L.A. Inflammation and wound healing: The role of the macrophage. Expert Rev. Mol. Med. 2011, 13, e23.
74. Smigiel, K.S.; Parks, W.C. Macrophages, Wound Healing, and Fibrosis: Recent Insights. Curr. Rheumatol. Rep. 2018, 20, 17I.
75. Butler, D.L. Anterior cruciate ligament: Its normal response and replacement. J. Orthop. Res. 1989, 7, 910–921.
76. Amiel, S.; Kuiper, S. Experimental studies on anterior cruciate ligament grafts. In Knee Ligaments: Structure, Function, Injury and Repair; Daniel, D., Ed.; Raven Press: Baltimore, MD, USA, 1990; pp. 379–388.
77. Davarinos, N.; O’Neill, B.J.; Curtin, W.A. Brief History of Anterior Cruciate Ligament Reconstruction. Adv. Orthop. Surg. 2014, 706042.
78. Galili, U.; LaTemple, D.C.; Radic, M.Z. A sensitive assay for measuring α-gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation 1998, 65, 1129–1132.
79. Van Der Merwe, W.; Lind, M.; Faunø, P.; Van Egmond, K.; Zaffagnini, S.; Marcacci, M.; Cugat, R.; Verdonk, R.; Ibañez, E.; Guillen, P. et al. Xenograft for anterior cruciate ligament reconstruction was associated with high graft processing infection. J. Exp. Orthop. 2020, 7, 79.
80. Little, D.; Thompson, J.W.; Dubois, L.G.; Ruch, D.S.; Moseley, M.A.; Guilak, F. Proteomic differences between male and fe-male anterior cruciate ligament and patellar tendon. PLoS ONE 2014, 9, e96526.
81. Kodigepalli K. M.; Thatcher K.; West T, Howsmon D.P.; Schoen F.J.; Sacks M.S.; Breuer C.K.; Lincoln J. Biology and Biome-chanics of the Heart Valve Extracellular Matrix. J. Cardiovasc Dev. Dis. 2020; 7, 57.
82. Naso, F.; Gandaglia, A.; Bottio, T.; Tarzia, V.; Nottle, M.B.; d’Apice, A.J.; Cowan, P.J.; Cozzi, E.; Galli, C.; Lagutina, I. et al. First quantification of α-gal epitope in current glutaraldehyde-fixed heart valve bioprostheses. Xenotransplantation 2013, 20, 252–261.
83. Zhu, A.; Monahan, C.; Zhang, Z.; Hurst, R.; Leng, L.; Goldstein, J. High-level expression and purification of coffee bean α-galactosidase produced in the yeast Pichia Pastoris. Arch. Biochem. Biophys. 1995, 324, 65–70.
84. Dor, F.J.; Tseng, Y.L.; Cheng, J.; Moran, K.; Sanderson, T.M.; Lancos, C.J.; Shimizu, A.; Yamada, K.; Awwad, A.; Sachs, D.H. et al. α1,3-Galactosyltransferase gene-knockout miniature swine produce natural cytotoxic anti-Gal antibodies. Transplantation 2004, 78, 15–20.
85. Fang, J.; Walters, A.; Hara, H.; Long, C.; Yeh, P.; Ayares, D.; Cooper, D.K.; Bianchi, J. Anti-gal antibodies in α1,3-galactosyltransferase gene knockout pigs. Xenotransplantation 2012, 19, 305–310.
86. Galili, U. α1,3Galactosyltransferase knockout pigs produce the natural anti-Gal antibody and simulate the evolutionary appearance of this antibody in primates. Xenotransplantation 2013, 20, 267–276.
87. Liao, K.; Seifter, E.; Hoffman, D.; Yellin, E.L.; Frater, R.W. Improved postfixation treatment of glutaraldehyde fixed porcine aortic valves by monosodium glutamate. Artif. Organs 1992, 16, 267–272.
88. Shang, H.; Claessens, S.M.; Tian, B.; Wright, G.A. Aldehyde reduction in a novel pericardial tissue reduces calcification using rabbit intramuscular model. J. Mater. Sci. Mater. Med. 2017, 28, 16.
89. Zabirnyk, A.; Ferrer, M.D.; Bogdanova, M.; Pérez, M.M.; Salcedo, C.; Kaljusto, M.L.; Kvitting, J.P.; Stensløkken, K.O.; Perelló, J.; Vaage, J. SNF472, a novel anti-crystallization agent, inhibits induced calcification in an in vitro model of human aortic valve calcification. Vasc. Pharmacol. 2019, 122–123, 106583.
90. Shen, S.H.; Sung, H.W.; Tu, R.; Hata, C.; Lin, D.; Noishiki, Y.; Quijano, R.C. Characterization of a polyepoxy compound fixed porcine heart valve bioprosthesis. J. Appl. Biomater. 1994, 5, 159–162.
91. van Wachem, P.B.; Brouwer, L.A.; Zeeman, R.; Dijkstra, P.J.; Feijen, J.; Hendriks, M.; Cahalan, P.T.; van Luyn, M.J. In vivo behavior of epoxy-crosslinked porcine heart valve cusps and walls. J. Biomed. Mater. Res. 2000, 53, 18–27.
92. Girardot, J.M.; Girardot, M.N. Amide cross-linking: An alternative to glutaraldehyde fixation. J. Heart Valve Dis. 1996, 5, 518–525.
93. Leong, J.; Munnelly, A.; Liberio, B.; Cochrane, L.; Vyavahare, N. Neomycin and carbodiimide crosslinking as an alternative to glutaraldehyde for enhanced durability of bioprosthetic heart valves. J. Biomater. Appl. 2013, 27, 948–960.
94. Sacks, M.S.; Schoen, F.J. Collagen fiber disruption occurs independent of calcification in clinically explanted bioprosthetic heart valves. J. Biomed. Mater. Res. 2002, 62, 359–371.